Alitretinoin topical - Ligand Pharmaceuticals

Drug Profile

Alitretinoin topical - Ligand Pharmaceuticals

Alternative Names: 9-cis Retinoic acid; 9-CRA; ALRT 1057; LG 1057; LGD 1057; LGN 1057; Panretin

Latest Information Update: 17 Mar 2015

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Kaposi's sarcoma

Most Recent Events

  • 13 Mar 2015 Launched for Kaposi's sarcoma in Argentina (Topical) before March 2015
  • 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
  • 06 Nov 2006 Eisai has completed the acquisition agreement for exclusive global rights to alitretinoin 0.1% gel from Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top